←NVONovo Nordisk A/SOur view: AttractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Novo Nordisk makes the weight-loss and diabetes drugs Ozempic and Wegovy

Ozempic

an injection for diabetes

Wegovy

the same medicine for weight loss, as an injection or pill

Insulin

and medicines for rare diseases

Its main medicines copy a gut hormone called GLP-1, which cuts appetite and controls blood sugar. Patients lose about a sixth of their weight. Novo is a Danish company.

The company · 2 · What exactly does it sell?

Three quarters of sales come from one medicine

Each $1 of sales, first half of 2026
47%30%17%6%1%
Diabetes: Ozempic and pillsWeight loss: WegovyInsulinRare diseasesOther diabetes care

Ozempic and Wegovy share one active ingredient, semaglutide. Governments, insurers and patients pay per month of treatment.

The company · 3 · How does it make money?

It keeps over 40 cents of each sales dollar as profit

41 to 44 centsprofit per sales dollar, steady from 2021 to 2025
4.5% → 19.5%of sales now spent on new factories
+2%whole-company growth in the first half

A drug is expensive to discover but cheap to make, so a successful one is very profitable. Weight-loss sales grew 19%, but US prices fell and diabetes sales slowed.

Is it a good business? · 4 · What gives it an edge?

Patents stop copies, but not a better rival

About 2032

when US copies of its main ingredient can start

21% vs 2%

weight lost on its next drug, CagriSema, against diet alone

4.9 million

weight-loss patients it treats

A patent keeps exact copies out until it ends. It does nothing to stop a rival with a different, better drug, which is what happened.

Is it a good business? · 5 · What is the catch?

Lilly leads both its markets and has a longer patent

+48%Lilly's sales growth in the June quarter
2036Lilly's US patent ends, four years after Novo's
-22%US Wegovy injection sales in June, on lower prices

Listed rivals: LLY · CIPLA.NS · SDZ.SW · PFE

Eli Lilly took the US lead in 2025, and its next drug may be filed early in 2027. Generic makers such as Cipla and Sandoz already challenge Novo's patents, and pharmacies sell unapproved copies.

Is it a good business? · 6 · What does its record show?

Sales doubled in five years; now growth has nearly stopped

Sales, third quarter+4%at steady exchange rates
Wegovy pill salesDKK 5.4Bin the quarter
Profit per share-12%against a year earlier

The new pill is the fastest US launch of this kind of drug. But lower US prices are cancelling out the extra patients.

Is it a good business? · 7 · How much room is there to grow?

Patients are not the limit; the price is

890 millionadults worldwide living with obesity
About $2,700a year paid per patient
12%of American adults already take one of these drugs

Demand is huge, but the price per patient is falling as the US government's Medicare and cash buyers pay far less than the list price.

Is it a good business? · 8 · Who is in charge?

A charity controls it, and a new team is cutting costs

Since 2025Mike Doustdar as chief executive
About 9,000jobs cut since he took over
77.3%of votes held by a charitable foundation

Outside shareholders cannot force change. The finance chief leaves in December. Pay depends on sales and profit growth, none on the share price or cash.

The story right now · 9 · Why did these drugs boom?

A new kind of drug made real weight loss possible

21% vs 2%weight lost on CagriSema against diet and exercise alone
12%of American adults take one already
$274 a monthwhat Medicare will pay from 2027

For decades no medicine helped much with obesity. These drugs do, so demand exploded. Now governments are pushing prices down so more people can get them, and Novo and Lilly compete hard on price.

The story right now · 10 · How can sales stall with more patients?

More patients can still mean flat sales

  1. More people get treated4.9 million on its weight-loss drugs.
  2. Prices fall fasterA US price cut starts on 1 January.
  3. Sales go flatVolume up, price per patient down.
  4. Then the patent endsCheap copies arrive around 2032.

Sales are patients times the price each pays. Novo is winning patients but losing on price. The question is whether volume grows faster than price falls, until copies arrive.

The story right now · 11 · What changed lately?

The outlook rose again as the pill grew

+4%third-quarter sales
DKK 5.4BWegovy pill sales in the quarter
-13%US Wegovy injection sales, a smaller fall than June's
-37%the shares in the year to October

Solid quarter

The shares fell while sales per share rose, so the whole fall was investors paying less per dollar of sales. US regulators decide on CagriSema by year-end.

The story right now · 12 · What is everyone arguing about?

Is Novo's fade already in the price?

Many investors think

A fading leader that deserves to keep sliding

We think

The fade is real, but slower than feared and already in the price

The problem is price, not demand: Novo still gains patients. Against us, analysts expect 2027 profit below 2026, and Lilly's next drug may arrive soon after CagriSema.

The price and our view · 13 · What is a share worth?

The price sits about a third below our value

$61.61what we think a share is worth
$61.61our value
Attractive
below $49.29
Neutral
Unattractive
above $73.93
$35.80gloomy: sales fall faster and profit slips
$61.61our estimate: a fall next year, then modest growth
$78.91sunny: the recovery runs faster

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · How could we be wrong?

Prices fall faster, and Lilly keeps winning

US prices fall fasterBiggest

List prices drop sharply in January 2027.

Lilly keeps winningShowing now

Its drugs already lead in the US.

The patent endsWatch

Generic makers have already filed.

Price per patientUnknown

What Novo is paid after the 2027 cut.

About three quarters of sales come from one ingredient, so one drug's price decides the results. A late CagriSema would leave Novo without a new drug to sell.

The price and our view · 15 · How will we know?

The 2027 outlook on 3 February tests the fade

2027 sales expected to fall no more than 2%Good sign
US regulators approve CagriSemaGood sign
2027 sales expected to fall more than 5%We turn negative
FEB 20273

Full-year 2026 results and the 2027 outlook. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares rise to within a fifth of our estimate, the cushion is gone and we move to Neutral.

The price and our view · 16 · So, what do we think?

A fading weight-loss leader, priced for the fade

$61.61our value
Attractive
below $49.29
Neutral
Unattractive
above $73.93

AttractiveMedium conviction

Novo is still very profitable and gaining patients. The price sits near our gloomy case, so the decline is already paid for. Conviction is Medium because Lilly leads and US prices keep falling.

↑ ↓ to move · C for contents